Merluzzi S, Figini M, Colombatti A, Canevari S, Pucillo C
Immunology Section, Department of Biomedical Sciences and Technologies, Udine, Italy.
Adv Clin Path. 2000 Apr;4(2):77-85.
Antibodies have been used therapeutically to treat a variety of clinical conditions. The introduction of monoclonal antibodies (mAb) and, recently, engineered antibodies has greatly refined and expanded the therapeutic potential of this modality of treatment. Expanded use will depend on improvement in their efficacy (affinity and specificity), demonstration of their safety, and reduction of their immunogenicity depending on the size, suboptimal biodistribution and pharmacokinetics. To surmount these problems the molecules have to be redesigned and the basic issues of how monoclonal antibodies kill cells reinvestigated. The review will survey the literature for humanized antibodies in clinical trials and the perspective of the use of mAbs or engineered antibodies in clinical practice.
抗体已被用于治疗多种临床病症。单克隆抗体（mAb）以及最近的工程抗体的引入极大地完善并扩展了这种治疗方式的治疗潜力。其更广泛的应用将取决于疗效（亲和力和特异性）的提高、安全性的证明以及免疫原性的降低，而免疫原性又取决于分子大小、欠佳的生物分布和药代动力学。为克服这些问题，必须重新设计这些分子，并重新研究单克隆抗体杀死细胞的基本问题。本综述将调查临床试验中有关人源化抗体的文献，以及单克隆抗体或工程抗体在临床实践中的应用前景。
